The year in cardiovascular medicine 2021: diabetes and metabolic disorders.
Francesco CosentinoDeepak L BhattNikolaus MarxSubodh VermaPublished in: European heart journal (2022)
In the current paper, we review recently published studies that are helping us to understand how the treatment landscape for glucagon-like peptiide-1 receptor agonists and sodium glucose cotransporter 2 inhibitors is moving forward. We have also included relevant articles related to cardiovascular disease prevention in the setting of obesity, atherogenic dyslipidaemia and chronic kidney disease.
Keyphrases
- cardiovascular disease
- type diabetes
- chronic kidney disease
- metabolic syndrome
- end stage renal disease
- insulin resistance
- weight loss
- glycemic control
- weight gain
- single cell
- cardiovascular events
- cardiovascular risk factors
- high fat diet induced
- case control
- adipose tissue
- drug induced
- smoking cessation
- replacement therapy